Qualigen Therapeutics(US:QLGN) Sou Hu Cai Jing·2025-09-20 02:50Core Viewpoint - Faraday Future (FF) is taking significant steps to address its debt obligations while simultaneously investing in growth opportunities, particularly through a strategic investment in Qualigen Therapeutics, Inc. (QLGN) and the establishment of a creditor trust by its founder and Co-CEO Jia Yueting [1][3][4] Group 1: Debt Management and Trust Establishment - Jia Yueting announced the creation of a second creditor trust, committing to allocate 50% of his personal earnings from stock incentives and investment returns to repay debts under Chinese law, while the other half will be used for vehicle production [3] - The trust's establishment details will be disclosed in the future, emphasizing the company's commitment to fulfilling its debt obligations [3] Group 2: Strategic Investment in QLGN - FF is leading a strategic investment of $41 million in NASDAQ-listed Qualigen Therapeutics, Inc. (QLGN), with FF contributing approximately $30 million for about 55% ownership, while Jia Yueting personally invests $4 million for about 7% ownership [4] - Following the investment announcement, QLGN's stock surged by up to 111%, reflecting strong market interest [2][3] - After the transaction, FF and Jia Yueting will collectively hold approximately 62% of QLGN, with Jia Yueting taking on the role of Chief Advisor and FF's global president Jerry Wang becoming Co-CEO of QLGN [4] Group 3: Future Business Directions - QLGN will be rebranded as CXC10 and will focus on developing six major products under its Crypto "three-horse carriage" business model, aiming to become a leading player in the intersection of Web2, Web3, and EAI + Crypto sectors [4] - FF's Crypto business is positioned to become one of the fastest companies to achieve a split listing on NASDAQ [4]